Thursday, June 5, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Regeneron’s Weight-loss Drug Helps Patients on Wegovy Preserve Muscle

June 2, 2025
in Health News
Share on FacebookShare on Twitter


(Reuters) -Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk’s popular obesity drug Wegovy in a mid-stage trial.

In the 599-patient study, those on Wegovy alone lost about 7.9 pounds of muscle, while those on a combination of Regeneron’s trevogrumab and Wegovy lost up to 4.2 pounds.

The combination helped patients shed up to 11.3% of their body weight compared with 10.4% for those on only Wegovy.

The results mark an early win for Regeneron in the race against nearly a dozen companies to develop obesity treatments that preserve muscle, as they vie for a share of the potential $150 billion weight-loss drug market.

Regeneron also said it will license an experimental obesity drug from China’s Hansoh Pharmaceuticals in a deal worth up to $2.01 billion.

Weight-loss drugs from current market leaders Novo Nordisk and Eli Lily help patients shed fat but also lead to muscle loss, which can increase the risk of falls and decrease overall strength.

Several companies, including Lilly and smaller rivals Scholar Rock and Veru are working on drugs that target proteins tied to muscle preservation or growth, but they are all years away from approval.

Veru’s drug, enobosarm, has shown to help older patients on Wegovy lose 71% less muscle compared to the Novo drug alone in a mid-stage trial. Data from Lilly and Scholar Rock is expected later this year.

The U.S. Food and Drug Administration has said these drugs need to show additional weight loss or other benefits, such as improvement in patients’ strength, to be considered for approval. But it has not given clear guidance on what data will be enough for approval.

Wall Street analysts have said that an unclear regulatory path and showing clean safety are key challenges for companies developing muscle-preserving drugs.

A triple drug combination of Wegovy, Regeneron’s trevogrumab and another antibody garetosmab helped patients lose 13.2% of their body weight. But 28% of the patients stopped treatment due to side effects – the highest rate among all groups tested in the study.

“Incremental improved weight loss from double and triple therapy are promising,” said BMO Capital Markets analyst Evan Seigerman, adding that late stage data will be crucial to understand safety profile of Regeneron’s drug.

Two patients in the triple combination group died, Regeneron said, adding that it has not yet identified if the deaths were connected to the treatment.

Regeneron expects full data from the study later this year.

(Reporting by Mariam Sunny in Bengaluru and Bhanvi Satija in New York; Editing by Shailesh Kuber and Shinjini Ganguli)



Source link : https://www.medscape.com/s/viewarticle/regeneron-says-its-weight-loss-drug-helped-preserve-muscle-2025a1000ete?src=rss

Author :

Publish date : 2025-06-02 11:12:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

Measles Update: Where Are We Now?

Next Post

Latvia Reports Bird Flu in Backyard Poultry

Related Posts

Health News

Combination Therapy Offers CONFIDENCE to CKD+T2D Patients

June 5, 2025
Health News

Do Doctors Need More ‘Sacred Moments’ in Medicine?

June 5, 2025
Health News

A Town’s Worth of Endoscopy Waste; IBS Drug Toxicity; E. Coli-Tainted Ground Beef

June 5, 2025
Health News

Ranibizumab Ocular Implant Shows Long-Term Benefits in Retinal Disease

June 5, 2025
Health News

Setting Up a Successful Fracture Liaison Service

June 5, 2025
Health News

Picking the Right Osteoanabolic Agent First, and What Comes Next

June 5, 2025
Load More

Combination Therapy Offers CONFIDENCE to CKD+T2D Patients

June 5, 2025

Do Doctors Need More ‘Sacred Moments’ in Medicine?

June 5, 2025

A Town’s Worth of Endoscopy Waste; IBS Drug Toxicity; E. Coli-Tainted Ground Beef

June 5, 2025

Ranibizumab Ocular Implant Shows Long-Term Benefits in Retinal Disease

June 5, 2025

Setting Up a Successful Fracture Liaison Service

June 5, 2025

Picking the Right Osteoanabolic Agent First, and What Comes Next

June 5, 2025

EPA Moves to Roll Back Rules Projected to Save Thousands of Lives and Billions of $$

June 5, 2025

A Double Threat to Allergy Patients

June 5, 2025
Load More

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version